Insmed Incorporated (NASDAQ:INSM) was the recipient of unusually large options trading activity on Monday. Investors bought 1,584 put options on the stock. This represents an increase of 1,550% compared to the typical daily volume of 96 put options.
INSM stock opened at $23.08 on Tuesday. Insmed has a 52 week low of $11.31 and a 52 week high of $33.13. The business has a 50-day simple moving average of $19.54 and a 200 day simple moving average of $20.72. The company has a quick ratio of 6.70, a current ratio of 6.97 and a debt-to-equity ratio of 1.19. The company has a market cap of $2.06 billion, a PE ratio of -5.53 and a beta of 3.04.
Insmed (NASDAQ:INSM) last issued its earnings results on Wednesday, October 30th. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.67) by ($0.01). The business had revenue of $38.89 million during the quarter, compared to analyst estimates of $35.89 million. Insmed had a negative net margin of 291.19% and a negative return on equity of 114.68%. During the same period in the prior year, the business posted ($1.14) EPS. On average, analysts anticipate that Insmed will post -2.91 EPS for the current fiscal year.
In related news, CAO John Goll sold 25,000 shares of the stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $20.80, for a total transaction of $520,000.00. Company insiders own 4.95% of the company’s stock.
Large investors have recently bought and sold shares of the company. Point72 Hong Kong Ltd bought a new position in Insmed during the second quarter worth $34,000. Riverhead Capital Management LLC acquired a new position in Insmed during the 2nd quarter valued at about $73,000. NumerixS Investment Technologies Inc boosted its stake in Insmed by 26.5% during the 2nd quarter. NumerixS Investment Technologies Inc now owns 4,807 shares of the biopharmaceutical company’s stock valued at $123,000 after purchasing an additional 1,007 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Insmed by 17.2% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,818 shares of the biopharmaceutical company’s stock worth $103,000 after purchasing an additional 854 shares in the last quarter. Finally, Tyers Asset Management LLC grew its holdings in Insmed by 1,002.5% during the second quarter. Tyers Asset Management LLC now owns 7,056 shares of the biopharmaceutical company’s stock worth $181,000 after buying an additional 6,416 shares in the last quarter.
A number of brokerages have recently issued reports on INSM. Goldman Sachs Group began coverage on shares of Insmed in a report on Tuesday, September 3rd. They issued a “buy” rating and a $30.00 target price on the stock. ValuEngine raised Insmed from a “hold” rating to a “buy” rating in a research report on Monday, November 25th. Credit Suisse Group restated a “buy” rating and issued a $40.00 price objective on shares of Insmed in a research note on Tuesday, September 10th. HC Wainwright reaffirmed a “buy” rating on shares of Insmed in a research report on Thursday, October 31st. Finally, Morgan Stanley set a $37.00 target price on Insmed and gave the stock a “buy” rating in a research note on Friday, November 1st. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $35.88.
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.
Read More: Most Volatile Stocks
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.